Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Jubilant Pharmova has informed that it enclosed a press release pertaining to receipt of Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for radiopharmaceuticals manufacturing facility of subsidiary company Jubilant Draximage Inc., at Montreal Canada.
The above information is a part of company’s filings submitted to BSE.